Gilead Sciences (GILD) Change in Receivables (2009 - 2026)

Gilead Sciences (GILD) has reported Change in Receivables for 18 consecutive years, with $333.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables rose 14.04% year-over-year to $333.0 million; the trailing twelve-month figure through Jun 2026 stood at $353.0 million (up 1780.95% YoY), and the FY2025 full-year result was $367.0 million, up 364.03% from the prior year.
• Change in Receivables advanced to $333.0 million in Q2 2026 per GILD's latest filing, from -$134.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $612.0 million in Q3 2023 and bottomed at -$699.0 million in Q1 2022.
• Historically, Change in Receivables has averaged $37.6 million across 5 years, with a median of $47.5 million in 2024.
• The widest YoY moves for Change in Receivables: up 906.9% in 2025, down 219.7% in 2025.
• Over 5 years, Change in Receivables stood at $281.0 million in 2022, then slumped by 178.29% to -$220.0 million in 2023, then jumped by 67.27% to -$72.0 million in 2024, then slumped by 148.61% to -$179.0 million in 2025, then jumped by 286.03% to $333.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $333.0 million, -$134.0 million, and -$179.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.